# Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

> **NCT03291028** · — · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 16 (estimated)

## Conditions studied

- Renal Cell Carcinoma
- Urothelial Carcinoma
- Bladder Cancer
- Ureter Cancer
- Urethral Cancer

## Interventions

- **BIOLOGICAL:** Immune checkpoint inhibitor targeting PD1

## Key facts

- **NCT ID:** NCT03291028
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2017-11-27
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03291028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03291028, "Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03291028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*